Cellebrite DI Ltd. - Ordinary Shares (CLBT)

A high-conviction fund just trimmed one of its biggest winners—here’s what long-term investors should make of the move.

A specialist small-cap fund just doubled down on a digital-intelligence company that's underperforming the broader market.

One fund just took a step back from a struggling energy name—right as the company suspended its dividend to fund future growth.

Cellebrite just served up some great news for investors with its latest quarterly report.

Cellebrite (CLBT) Q3 2025 Earnings Call Transcript

Looking for insights into the US markets in the middle of the day on Thursday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

The market is buzzing with gapping stocks on Thursday. Let's uncover which stocks are experiencing notable gaps during today's session.

The US market session of Thursday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.

As the regular session of the US market on Wednesday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.

Cellebrite experienced solid growth in Q2 2025, exceeding expectations for sales and earnings. Signs of a rebound are encouraging.

Cellebrite reports mixed Q2 2025 results: revenue slightly misses estimates at $113.3M, while EPS beats at $0.12. New CEO appointed amid leadership changes and strategic acquisitions. Stock dips pre-market.

The Benzinga Stock Whisper Index looks at five stocks seeing increased attention from readers during the week and a look at what could be causing the increased interest.